<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869869</url>
  </required_header>
  <id_info>
    <org_study_id>ASMF-Scheer</org_study_id>
    <nct_id>NCT00869869</nct_id>
  </id_info>
  <brief_title>Melatonin Supplementation to Improve Sleep in Patients With Heart Failure</brief_title>
  <official_title>Restoration of Sleep in Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Academy of Sleep Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether melatonin can improve sleep, quality of
      life and markers of heart failure in patients with heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure affects nearly 5 million individuals in the United States and constitutes a
      prime risk factor for morbidity and mortality. Beta-blockers are a class of drugs that form a
      critical part of the best treatment of heart failure, and thereby decrease the risk for these
      serious problems. Beta-blockers also lower the levels of melatonin, a hormone that has a
      sleep-promoting effect. Most patients with heart failure take beta-blockers and have poor
      sleep, which may be related to the beta-blockers' effect on melatonin levels. This study will
      evaluate the effectiveness of treatment with melatonin supplements in improving sleep in
      individuals with heart failure who are taking beta-blockers. In addition, the study will
      examine whether the melatonin supplements aid in improving quality of life and measures of
      heart failure.

      Participants in this double-blind study will be randomly assigned to receive either melatonin
      supplements or placebo for the duration of the study.

      The study will mainly take place at home, where participants will complete sleep diaries,
      measure blood pressure and wear a wrist watch that measures movement for 5-6 weeks. During
      that time there will be three visits to the hospital where plasma and urine samples will be
      collected and questionnaires will be completed.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects were enrolled in this study. Funding ran out.
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sleep quantity assessed by actigraphy</measure>
    <time_frame>measured during ambulatory phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life and heart failure biomarkers</measure>
    <time_frame>measured during study visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <condition>Sleep Disorders</condition>
  <arm_group>
    <arm_group_label>melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks</description>
    <arm_group_label>melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with heart failure NYHA Class 2 or 3

          -  Currently being treated with beta-blocker

        Exclusion Criteria:

          -  Diagnosed with obstructive sleep apnea

          -  Using Fluvoxamine, Warfarin, Nifedipine, or Calcium Channel Blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A.J.L. Scheer, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://sleep.med.harvard.edu/people/faculty/242/Frank+A+J+L+Scheer+PhD</url>
    <description>Faculty Profile: Frank A.J.L. Scheer, Ph.D.</description>
  </link>
  <link>
    <url>http://sleep.med.harvard.edu/research/labs/54/Medical+Chronobiology+Program</url>
    <description>Medical Chronobiology Program</description>
  </link>
  <reference>
    <citation>Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004 Feb;43(2):192-7. Epub 2004 Jan 19.</citation>
    <PMID>14732734</PMID>
  </reference>
  <reference>
    <citation>Scheer FA, Czeisler CA. Melatonin, sleep, and circadian rhythms. Sleep Med Rev. 2005 Feb;9(1):5-9. Review.</citation>
    <PMID>15649734</PMID>
  </reference>
  <reference>
    <citation>Scheer FA, Zeitzer JM, Ayas NT, Brown R, Czeisler CA, Shea SA. Reduced sleep efficiency in cervical spinal cord injury; association with abolished night time melatonin secretion. Spinal Cord. 2006 Feb;44(2):78-81.</citation>
    <PMID>16130027</PMID>
  </reference>
  <reference>
    <citation>Scheer FA. Potential use of melatonin as adjunct antihypertensive therapy. Am J Hypertens. 2005 Dec;18(12 Pt 1):1619-20.</citation>
    <PMID>16364835</PMID>
  </reference>
  <reference>
    <citation>Scheer FA, Stone PH, Shea SA. Decreased sleep in heart failure: are medications to blame? Arch Intern Med. 2007 May 28;167(10):1098-9; author reply 1099-100.</citation>
    <PMID>17533214</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Frank AJL Scheer, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Sleep Disorders</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Central Nervous System Depressants</keyword>
  <keyword>Protective Agents</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Signs and Symptoms</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Central Nervous System Depressants</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

